Circulating biomarkers in melanoma immunotherapy
Posted 29th June 2021 by Nicholas Noakes
Genevieve Boland, speaking at the Research & Technology Series, described the translational research conducted at her laboratory. Using tumour and blood samples from patients before treatment, at meaningful clinical changes, progression, and post-mortem she, and her team are trying to understand the biology of Melanoma to treat patients better.
Cell therapies: opportunities and challenges
Posted 20th May 2020 by Joshua Sewell
This article is republished with kind permission from BioVox.
Recent activities in the cell therapy field have prompted many investment funds to pour fresh and increasing capital into this space. In this review, we would like to share some observations and highlight a few of the questions that arise when new modalities cross the bridge from bench to bed.
Improving the selection of candidate CD8+ T cell epitopes for immunotherapy
Posted 6th January 2020 by Joshua Sewell
Alongside the talks at our conferences, the poster presentations are a huge part of the knowledge sharing that takes place. We’re thrilled to be able to take a closer look at this poster from the Research & Technology Series, presented by Wim van Esch and the team at Sanquin.
A 14 colour antibody panel: developing a tool and demonstrating a process
Posted 7th June 2019 by Joshua Sewell
One of the frustrations I have with Flow Cytometry is when companies present their amazing new findings at conferences, and it’s quite often about TMB cells. In my case, I work on these cells perhaps 20% of the time. The rest of the time I work on cells from other parts of the human body – bone marrow, lung, bronchoalveolar lavage, spleen – and in diverse animals such as mice, rats, and even sparrow, chicken, and mosquito.
Determining the fate of cells with Flow Cytometry
Posted 31st May 2019 by Joshua Sewell
The ability to measure multiple forms of cell death simultaneously represents a significant development for such techniques. I have been using antibodies and more specific forms of dyes to identify mitochondrial activity and reactive oxygen in roughly fifty populations, whereas normally it would only be able to measure one at a time. I will be discussing this work at the Flow Cytometry Congress, and it could prove enormously beneficial to drug and immunotherapy development.
Personalised Cancer Vaccines for Mesothelioma
Posted 26th September 2018 by Jane Williams
Immunotherapy continues to gain popularity in several areas related to cancer research and new treatments. Studies prove that each and every cancer case is unique, so the need for personalised medicine presents a logical focus. Personalised cancer vaccines are one form of cancer immunotherapy. The vaccines are a form of precision medicine, which has become an increasingly more enticing area for treatment research.
Precision Medicine: An open letter from Miro Venturi
Posted 17th July 2017 by Jane Williams
Dear Colleagues,
In recent times, we have seen advances in precision medicine lead to powerful discoveries and improved patient care. Liquid biopsies for example, now have the potential to be a real game-changer in cancer testing and could revolutionise cancer care.
Upcoming Developments in Precision Medicine
Posted 8th May 2017 by Jane Williams
Future of immunotherapies
Immunotherapies are on the fast growth trajectory which will be moderated based on responder groups, toxicity and efficacy results and high costs and increasingly used in combination therapies. The overall immune oncology checkpoint inhibitor market was over $2.0 billion and is set to grow to $14 billion by 2018.